Drugs / GURETOLIMOD
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03416335 | Jun 2018 → Dec 2022 | neoplasm | Sumitomo Pharma America, Inc. | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GURETOLIMOD | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314554 ↗ |
| Known as | DSP-0509 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03416335 ↗ |
| Known as | DSR-106509 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314554 ↗ |
| Action | Activate | “DSP-0509, a Synthetic Toll-Like Receptor 7 (TLR-7) Agonist” NCT03416335 ↗ |
| Modality | Small molecule | — CHEMBL5314554 ↗ |
| Route | Intravenous | “administered as a constant rate IV infusion over 10 minutes using a syringe pump” NCT03416335 ↗ |
| Target | TLR7 | “DSP-0509, a Synthetic Toll-Like Receptor 7 (TLR-7) Agonist” NCT03416335 ↗ |